Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
| ▸ | XPO1 | O14980 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998165 | 0.97 | IDO1 (0.46) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| SCHEMBL25112073 | 0.87 | MAPT (0.43) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| Hydrochloric Acid SCHEMBL28844636 | 0.85 | ACP1 (0.46) | IDO1XPO1GPR35ACP1P2RX4 | |
| Hydrochloric Acid SCHEMBL4376336 | 0.85 | RAPGEF4 (0.51) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| SCHEMBL997922 | 0.84 | HDAC3 (0.42) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| SCHEMBL11677821 | 0.82 | RAPGEF4 (0.52) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| SCHEMBL4374429 | 0.82 | RAPGEF4 (0.53) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| SCHEMBL25112072 | 0.79 | TACR1 (0.35) | IDO1MAPTRAPGEF4XPO1GPR35 | |
| Hydrochloric Acid SCHEMBL1309809 | 0.78 | ALDH1A1 (0.59) | IDO1MAPTRAPGEF4LMNAALDH1A1 | |
| SCHEMBL25112282 | 0.78 | IDO1 (0.44) | IDO1MAPTRAPGEF4XPO1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119674192-A | PVDF-based organic-inorganic composite polymer solid electrolyte and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-114276305-A | Tri-substituted phenyl-1, 2, 4-triazole derivative, preparation thereof and application thereof in treating neuronal injury | 中山大学 | 2022-04-05 | — | — | CN | claimed |
| CN-121908732-A | Hole transport layer, perovskite solar cell and preparation method | 湖州市鹑火光电有限公司 | 2026-04-21 | — | — | CN | disclosed |
| CN-119674192-A | PVDF-based organic-inorganic composite polymer solid electrolyte and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114621121-B | Preparation method of camphorsulfonyl hydrazides compound, camphorsulfonyl hydrazides compound product and application of camphorsulfonyl hydrazides compound product | 南京林业大学 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-114276305-B | Trisubstituted phenyl-1, 2, 4-triazole derivative, preparation method thereof and application thereof in treatment of neuronal injury | 中山大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-114621121-A | Preparation method of camphor sulfonyl hydrazine compound, product and application thereof | 南京林业大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-114276305-A | Tri-substituted phenyl-1, 2, 4-triazole derivative, preparation thereof and application thereof in treating neuronal injury | 中山大学 | 2022-04-05 | — | — | CN | disclosed |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-04 | — | — | US | disclosed |
| EP-3848353-A1 | MEDICAMENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| WO-2016171743-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2015164482-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-1874871-B1 | WATER SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LTD (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2270106-A2 | Indolium compounds containing fluoro-substituents | GE Healthcare UK Limited (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100249385-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-7767829-B2 | Water-soluble fluoro-substituted cyanine dyes as reactive fluorescence labelling reagents | GE HEALTHCARE UK LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-20090252687-A1 | ASYMMETRIC FLUORO-SUBSTITUTED POLYMETHINE DYES | COOPER MICHAEL EDWARD | 2009-10-08 | — | — | US | disclosed |
| US-20060239922-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-0001019-A1 | Phenylhydrazones, their use in insecticidal compositions and methods for their preparation | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239922-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | TPD52L2, MRPL21, MRPL9 | CA2 1581/4885IDO1 4184/4885MAPT 3088/4885 |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | CA2 4610/4885IDO1 4763/4885MAPT 2734/4885 |
| US-20090252687-A1 | ASYMMETRIC FLUORO-SUBSTITUTED POLYMETHINE DYES | FCGR2A, FCGR3B, FCER2 | CA2 2851/4885IDO1 108/4885MAPT 2218/4885 |
| US-20100249385-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | TPD52L2, MRPL9, MRPL21 | CA2 1597/4885IDO1 4199/4885MAPT 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.